Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

Capodanno, Davide; Patel, A.; Dharmashankar, Kodlipet; Ferreiro, José Luis; Ueno, Masashi; Kodali, Murali; Tomasello, Salvatore D.; Capranzano, Piera; Seecheran, Naveen; Darlington, Andrew; Tello, Antonio; Desai, Bhaloo; Bass, Theodore A.; Angiolillo, Dominick J.

doi:10.1016/s0735-1097(11)61910-4

Cited by 16 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 To further optimize treatment with aspirin in patients with enhanced platelet turnover, a higher frequency of aspirin administration and possibly a higher daily dosage are currently being discussed. 35,[44][45][46][47][48][49] In diabetic patients, the enhancement of platelet turnover can be significantly counteracted by a twice daily aspirin regimen. 44,[48][49][50] Recently, a study of patients with type 2 diabetes and stable coronary artery disease demonstrated that doubling the frequency of aspirin administration but not doubling the once daily dose enhances platelet inhibition.…”

Section: Mechanisms Of Action and Dosage Of Aspirinmentioning

confidence: 99%

“…44,[48][49][50] Recently, a study of patients with type 2 diabetes and stable coronary artery disease demonstrated that doubling the frequency of aspirin administration but not doubling the once daily dose enhances platelet inhibition. 48 Improved laboratory responses on twice daily dosing have also been reported by other investigators. 38,44,49 A lack of adherence, however, is also to be considered to be a very frequent cause of inadequate benefit from aspirin prescription.…”

Section: Mechanisms Of Action and Dosage Of Aspirinmentioning

confidence: 99%

See 1 more Smart Citation

Primary and secondary prevention of cardiovascular disease in diabetes with aspirin

Schnell

Erbach²,

Hummel

2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Diabetes is associated with an increased cardiovascular risk. The role for aspirin in diabetes is of high clinical interest. Guidelines recommend that primary prevention of cardiovascular disease (CVD) in diabetes with aspirin should be based on the individual risk for CVD. New mechanistic studies suggest that enhanced platelet turnover may partly contribute to the fact the primary prevention studies found unequivocal results in diabetes. There is initial evidence that a potential future modification of dosages in diabetes may counteract the enhancement in platelet turnover in diabetes. The use of aspirin in diabetic patients for secondary prevention of CVD is supported by key evidence. The aim of the review is to present recent studies on aspirin for prevention of CVD in diabetes and to highlight its role also in view of new mechanistic and clinical studies with aspirin. Novel aspects of aspirin, e.g. its potential role for the prevention of cancer, are also presented.

show abstract

Section: Mechanisms Of Action and Dosage Of Aspirinmentioning

confidence: 99%

Section: Mechanisms Of Action and Dosage Of Aspirinmentioning

confidence: 99%

Primary and secondary prevention of cardiovascular disease in diabetes with aspirin

Schnell

Erbach²,

Hummel

2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

show abstract

“…Furthermore, ASA-treated patients who experienced MIs had significantly higher serum TxB 2 than ASA-treated patients who did not experience MIs. (36). We cannot exclude that a similar phenomenon may also occur in pneumonia and that another ASA regimen should therefore be adopted in this clinical setting.…”

mentioning

confidence: 96%

Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia

Cangemi

Casciaro

Rossi

et al. 2014

Journal of the American College of Cardiology

146

140

View full text Add to dashboard Cite

show abstract

“…25,26 Given that aspirin specifically targets COX-1, this agent is not effective in reducing platelet activation stimulated by other factors involved in arterial thrombosis, such as ADP and thrombin. 23,27 GP IIb/IIIa inhibitors The intravenous GP IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban) target the final pathway of platelet aggregation by competing with fibrinogen and vWF for binding to GP IIb/IIIa receptors. 28 They provide fast-acting and potent antiplatelet effects, and have been shown to improve ischaemic outcomes in patients with ACS undergoing percutaneous coronary intervention (PCI), even though in most of these studies patients were treated with ticlopidine or clopidogrel and not with a novel P2Y 12 -receptor inhibitor.…”

Section: Aspirinmentioning

confidence: 99%

Novel antiplatelet agents in acute coronary syndrome

2014

Self Cite

View full text Add to dashboard Cite

For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel oral P2Y purinoceptor 12 (P2Y12)-receptor inhibitors prasugrel and ticagrelor were approved by the FDA for clinical use in 2009 and 2011, respectively. These agents have a faster-acting, more-potent, and more-predictable antiplatelet effect than clopidogrel, which translates into improved clinical outcomes in patients with ACS, albeit at the expense of an increased risk of bleeding. However, some patients continue to experience adverse ischaemic events despite treatment with aspirin and a P2Y12-receptor antagonist, because platelets can remain activated via pathways not inhibited by these agents, such as the protease-activated receptor (PAR)-1 platelet activation pathway stimulated by thrombin. Emerging antiplatelet therapies that might address these limitations include intravenous P2Y12 antagonists, oral PAR-1 antagonists, and thromboxane-receptor inhibitors. In this Review, we provide an overview of these novel antiplatelet drugs, including newly approved agents and emerging compounds currently under clinical development, and also discuss evolving concepts and unmet needs related to antiplatelet therapy for the treatment of ACS.

show abstract

Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

Cited by 16 publications

References 0 publications

Primary and secondary prevention of cardiovascular disease in diabetes with aspirin

Primary and secondary prevention of cardiovascular disease in diabetes with aspirin

Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia

Novel antiplatelet agents in acute coronary syndrome

Contact Info

Product

Resources

About